Full text is available at the source.
Abstract
A woman in her 20s developed acute liver injury within four weeks of starting tirzepatide.
- Tirzepatide is primarily used for treating type 2 diabetes and obesity.
- Gastrointestinal side effects of tirzepatide are well documented, but hepatotoxicity has not been widely recognized.
- Recent case reports have linked tirzepatide to drug-induced liver injury.
- In this case, no alternative causes for the liver injury were identified after thorough investigation.
- The patient's liver function improved clinically and biochemically after stopping tirzepatide.
Simplified